NLS Selling And Marketing Expenses from 2010 to 2024

NLSPW Stock  USD 0.01  0  11.11%   
NLS Pharmaceutics Selling And Marketing Expenses yearly trend continues to be fairly stable with very little volatility. Selling And Marketing Expenses will likely drop to about 10.8 K in 2024. During the period from 2010 to 2024, NLS Pharmaceutics Selling And Marketing Expenses regression line of quarterly data had mean square error of 3.1 T and geometric mean of  1,355,961. View All Fundamentals
 
Selling And Marketing Expenses  
First Reported
2010-12-31
Previous Quarter
11.4 K
Current Value
10.8 K
Quarterly Volatility
1.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 137.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
  
Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Selling And Marketing Expenses Growth Pattern

Below is the plot of the Selling And Marketing Expenses of NLS Pharmaceutics AG over the last few years. It is NLS Pharmaceutics' Selling And Marketing Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.
Selling And Marketing Expenses10 Years Trend
Very volatile
   Selling And Marketing Expenses   
       Timeline  

NLS Selling And Marketing Expenses Regression Statistics

Arithmetic Mean2,636,603
Geometric Mean1,355,961
Coefficient Of Variation63.98
Mean Deviation951,970
Median2,491,622
Standard Deviation1,686,834
Sample Variance2.8T
Range6.5M
R-Value0.01
Mean Square Error3.1T
R-Squared0.000031
Significance0.98
Slope2,094
Total Sum of Squares39.8T

NLS Selling And Marketing Expenses History

202410.8 K
202311.4 K
20226.5 M
20215.9 M
20202.2 M

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Selling And Marketing Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling And Marketing Expenses11.4 K10.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.